Per standard of care, at the conclusion of the TORS procedure, liposomal bupivacaine will be injected into the surgical bed- (bupivacaine liposome suspension 1.3% [13.3 mg/mL], intramuscular) in this group. Possible injection sites include the base of tongue and/or tonsil. Total dose injected will be 3-4 mL. Subjects will also be given a pain regimen including:

1. Tylenol 650 mg every 4 hours as needed for mild pain
2. Oxycodone 5 mg every 4 hours as needed for moderate pain
3. Morphine 2mg every 3 hours as needed for breakthrough pain

The treatment type (TORS +/- Liposomal Bupivacaine + Postoperative Antipyretics and Opioids) is determined by the subject's surgeon based on his standard practice.

Per standard of care, subjects in this group will only be given a pain regimen including:

1. Tylenol 650 mg every 4 hours as needed for mild pain
2. Oxycodone 5 mg every 4 hours as needed for moderate pain
3. Morphine 2mg every 3 hours as needed for breakthrough pain

The treatment type (TORS +/- Liposomal Bupivacaine + Postoperative Antipyretics and Opioids) is determined by the subject's surgeon based on his standard practice.

We will inject liposomal bupivacaine into the surgical bed.

We will be measuring subjects' postoperative maximum visual analog pain scores on each postoperative day.

Scale: 0-10, 0 represents no pain and 10 represents the worst pain

Patients will undergo a functional endoscopic swallow study with a speech language pathologist during their first postoperative visit.

Patients will undergo an evaluation of their swallow function via the MD Anderson Dysphagia Inventory survey with a speech language pathologist during their first postoperative visit.

We will be measuring the doses of pain medication that patients requiring during their postoperative course.